Patents by Inventor Mavis Agbandje-McKenna
Mavis Agbandje-McKenna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10308957Abstract: Disclosed are capsid-modified rAAV particles and expression vectors, as well as compositions and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and using novel capsid-protein-mutated particle or rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian eye. Also disclosed are methods for subretinal delivery of therapeutic gene constructs to mammalian photoreceptors and retinal pigment epithelial cells, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications including the treatment of a variety of inherited retinal diseases.Type: GrantFiled: March 4, 2015Date of Patent: June 4, 2019Assignee: University of Florida Research Foundation, Inc.Inventors: Shannon E. Boye, Sanford L. Boye, Mavis Agbandje-McKenna, Arun Srivastava
-
Patent number: 10294281Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: GrantFiled: February 27, 2017Date of Patent: May 21, 2019Assignee: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
-
Publication number: 20190127424Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: ApplicationFiled: November 2, 2018Publication date: May 2, 2019Applicant: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Sergei Zolotukhin, Mavis Agbandje-McKenna, Kim M. Van Vliet, Li Zhong, Lakshmanan Govindasamy
-
Publication number: 20190048041Abstract: The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.Type: ApplicationFiled: September 28, 2016Publication date: February 14, 2019Inventors: Aravind Asokan, Mavis Agbandje-McKenna, Long Ping Victor Tse, Brittney Gurda
-
Publication number: 20190016759Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: ApplicationFiled: May 24, 2018Publication date: January 17, 2019Applicant: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Sergei Zolotukhin, Mavis Agbandje-McKenna, Kim M. Van Vliet, Li Zhong, Lakshmanan Govindasamy
-
Patent number: 10081659Abstract: A modified adeno-associated virus (AAV) capsid protein comprising at least one non-native amino acid that confers to the modified AAV particles new properties, such as increased transduction efficiency and reduced immunogenicity. These modified AAV proteins and particles are particularly useful for gene therapy and the treatment of various diseases and conditions.Type: GrantFiled: April 6, 2016Date of Patent: September 25, 2018Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, University of Florida Research Foundation, Inc.Inventors: John A. Chiorini, Sandra Wainer, Mavis Agbandje-McKenna, Sujata Halder
-
Publication number: 20180244727Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more symtpoms of disease or abnormal conditions via in situ and/or ex vivo mammalian gene therapy methods. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: ApplicationFiled: February 14, 2018Publication date: August 30, 2018Applicant: University of Florida Research Foundation, IncorporatedInventors: Li Zhong, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava
-
Publication number: 20180223312Abstract: Disclosed are next-generation multi-mutated capsid protein-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols. Also disclosed are large-scale production methods for the multi-mutated, capsid-modified rAAV expression vectors, viral particles, and infectious virions, as well as use of the disclosed compositions in the manufacture of medicaments for use in a variety of in vitro and/or in vivo therapeutic methodologies.Type: ApplicationFiled: November 28, 2017Publication date: August 9, 2018Applicant: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, Li Zhong, Sergei Zolotukhin, George Vladimirovich Aslanidi, Mavis Agbandje-McKenna, Kim M. Van Vliet, Chen Ling
-
Patent number: 10011640Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: GrantFiled: March 14, 2014Date of Patent: July 3, 2018Assignee: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, George Vladimirovich Aslanidi, Sergei Zolotukhin, Mavis Agbandje-McKenna, Kim M. Van Vliet, Li Zhong, Lakshmanan Govindasamy
-
Publication number: 20180135074Abstract: Provided herein are recombinant AAV (rAAV) particles comprising a nucleic acid vector comprising a parvovirus B 19p6 promoter operatively linked to a heterologous gene, such as a human globin gene, and rAAV capsid proteins comprising one or more amino acid substitutions in a surface exposed loop of the capsid protein that result, e.g., in increased P antigen binding compared to a corresponding un-mutated AAV capsid protein. Also provided are methods and compositions related to such capsid proteins, methods of targeting gene expression to a cell of erythroid lineage, methods of treating a hemoglobinopathy using such rAAV particles, and methods for efficient transduction of a host cell suspension with a rAAV.Type: ApplicationFiled: February 19, 2016Publication date: May 17, 2018Applicant: University of Florida Research Foundation, IncorporatedInventors: Arun Srivastava, Chen Ling, Mavis Agbandje-McKenna
-
Publication number: 20180105559Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: ApplicationFiled: August 8, 2017Publication date: April 19, 2018Applicant: University of Florida Research Foundation, Inc.Inventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
-
Patent number: 9920097Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more symptoms of disease or abnormal conditions via in situ and/or ex vivo mammalian gene therapy methods. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: GrantFiled: May 21, 2013Date of Patent: March 20, 2018Assignee: University of Florida Research Foundation, IncorporatedInventors: Li Zhong, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava
-
Publication number: 20180036428Abstract: Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors.Type: ApplicationFiled: August 18, 2017Publication date: February 8, 2018Applicant: University of Florida Research Foundation, IncorporatedInventors: Li Zhong, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava
-
Publication number: 20180030096Abstract: Provided herein are modified recombinant adeno-associated virus (rAAV) capsid proteins, such as modified rAAV1, rAAV5, and rAAV6 capsid proteins, rAAV particles comprising such capsid proteins, nucleic acid molecules encoding such capsid proteins, as well as compositions, kits and methods of use thereof.Type: ApplicationFiled: February 3, 2016Publication date: February 1, 2018Applicant: University of Florida Research Foundation, Inc.Inventors: George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna, Arun Srivastava
-
Patent number: 9775918Abstract: Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors.Type: GrantFiled: September 8, 2015Date of Patent: October 3, 2017Assignee: University of Florida Research Foundation, IncorporatedInventors: Li Zhong, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava
-
Publication number: 20170275337Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: ApplicationFiled: February 27, 2017Publication date: September 28, 2017Applicant: University of Florida Research Foundation, Inc.Inventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
-
Patent number: 9725485Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: GrantFiled: March 15, 2013Date of Patent: August 8, 2017Assignee: University of Florida Research Foundation, Inc.Inventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-McKenna
-
Patent number: 9611302Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.Type: GrantFiled: May 15, 2013Date of Patent: April 4, 2017Assignee: University of Florida Research Foundation, Inc.Inventors: Arun Srivastava, George Vladimirovich Aslanidi, Kim M. Van Vliet, Mavis Agbandje-Mckenna
-
Patent number: 9598468Abstract: Various aspects of the invention provide for capsids, parvovirus capsids, hybrid parvovirus capsids, parvovirus vectors, hybrid parvovirus vectors, hybrid parvovirus particles and parvovirus particles containing polypeptides in which the sequence YCDGFYACYMDV (SEQ ID NO: 3) has been substituted into the VP2 loop of the B19 capsid protein. Polypeptides in which the sequence YCDGFYACYMDV (SEQ ID NO: 3) has been substituted into the VP2 loop of the B19 capsid protein are also provided (e.g., SEQ ID NO: 2). Other aspects of the invention provides capsids, parvovirus capsids, hybrid parvovirus capsids, parvovirus vectors, hybrid parvovirus vectors, hybrid parvovirus particles and parvovirus particles containing a polypeptide comprising SEQ ID NO: 2. Also provided in various aspects of the invention a pharmaceutical compositions and methods of delivering therapeutic agents and/or reporter peptides/proteins to target cells.Type: GrantFiled: May 18, 2012Date of Patent: March 21, 2017Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventors: Kirsten Ariane Kelley Weigel-Van Aken, Mavis Agbandje-McKenna
-
Publication number: 20160369299Abstract: Disclosed are capsid-modified rAAV particles and expression vectors, as well as compositions and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and using novel capsid-protein-mutated particle or rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian eye. Also disclosed are methods for subretinal delivery of therapeutic gene constructs to mammalian photoreceptors and retinal pigment epithelial cells, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications including the treatment of a variety of inherited retinal diseases.Type: ApplicationFiled: March 4, 2015Publication date: December 22, 2016Applicant: University of Florida Research Foundation, Inc.Inventors: Shannon E. Boye, Sanford L. Boye, Mavis Agbandje-McKenna, Arun Srivastava